BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ultragenyx Pharmaceutical Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ultragenyx Pharmaceutical Inc.'s 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06636071-10813@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:setrusumab: Phase 3 readout est. (NCT06636071)
DESCRIPTION:setrusumab\, phase 3\, Osteogenesis Imperfecta.\nStudy: Setrusu
 mab in Pediatric Japanese Subjects With Osteogenesis Imperfecta\nEstimated
  primary completion: January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/setrusumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06636071
URL:https://assetmemo.bio/drug/setrusumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271186-1035@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Evkeeza (Evinacumab): Phase 2 readout est. (NCT07271186)
DESCRIPTION:Evkeeza (Evinacumab)\, phase 2.\nStudy: Study to Assess the Eff
 ects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease\nEstim
 ated primary completion: 13 October 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/evinacumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07271186
URL:https://assetmemo.bio/drug/evinacumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
